This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ballarè, E. Articles by Spada, A. Search for Related Content PubMed PubMed Citation Articles by Ballarè, E. Articles by Spada, A.

Mutation of Somatostatin Receptor Type 5 in an Acromegalic Patient Resistant to Somatostatin Analog Treatment

Institute of Endocrine Sciences, University of Milano 20122, Ospedale Maggiore IRCCS (E.B., A.G.L., M.F., S.C., S.M., M.A., P.B.-P., G.F., A.S.), 20122 Milan; and Istituto Auxologico Italiano IRCCS (L.P., E.G.), 20145 Milano, Italy

Address all correspondence and requests for reprints to: Anna Spada, M.D., Istituto di Scienze Endocrine Ospedale Maggiore, IRCCS, Via Francesco Sforza 35, 20122 Milano, Italy. E-mail: anna.spada{at}unimi.it

Abstract

Introduction of somatostatin analogs has greatly contributed to improving the prognosis of acromegaly. Although the majority of patients are effectively treated by these agents, resistance occurs in a subset of patients. So far, resistance to somatostatin has never been associated with mutations of the somatostatin receptor subtypes (sst2 and sst5) that inhibit GH secretion. Molecular analysis of genomic DNA from pituitary tumor and peripheral blood obtained from an acromegalic resistant to octreotide showed a somatic activating mutation of Gs (Arg201Cys), no mutation in sst2, and one polymorphism (Pro109Ser) and one germ line mutation (Arg240Trp) in sst5. Wild-type (WT) and mutant sst5 PCR products were cloned and transfected into Chinese hamster ovary K1 cells. In Chinese hamster ovary K1 cells stably expressing mutant sst5, somatostatin-28 was less potent in inhibiting cyclic AMP levels than in WT cells. Proliferation of mutant cells exceeded that of WT by 50%. Moreover, somatostatin reduced cell growth and MAPK activity in WT but not in mutant cells in which the peptide even increased MAPK activity. We suggest that this mutation that abrogates the antiproliferative action of somatostatin and activates mitogenic pathways may be involved in the resistance to somatostatin treatment.

This article has been cited by other articles:

				E. Peverelli, A. G. Lania, G. Mantovani, P. Beck-Peccoz, and A. Spada Characterization of Intracellular Signaling Mediated by Human Somatostatin Receptor 5: Role of the DRY Motif and the Third Intracellular Loop Endocrinology, July 1, 2009; 150(7): 3169 - 3176. [Abstract] [Full Text] [PDF]

				M. Grant, H. Alturaihi, P. Jaquet, B. Collier, and U. Kumar Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization Mol. Endocrinol., October 1, 2008; 22(10): 2278 - 2292. [Abstract] [Full Text] [PDF]

				E. Peverelli, G. Mantovani, D. Calebiro, A. Doni, S. Bondioni, A. Lania, P. Beck-Peccoz, and A. Spada The Third Intracellular Loop of the Human Somatostatin Receptor 5 Is Crucial for Arrestin Binding and Receptor Internalization after Somatostatin Stimulation Mol. Endocrinol., March 1, 2008; 22(3): 676 - 688. [Abstract] [Full Text] [PDF]

				E Ferrante, C Pellegrini, S Bondioni, E Peverelli, M Locatelli, P Gelmini, P Luciani, A Peri, G Mantovani, S Bosari, et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr. Relat. Cancer, September 1, 2006; 13(3): 955 - 962. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, and C. Y. Bowers Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition Endocr. Rev., April 1, 2006; 27(2): 101 - 140. [Abstract] [Full Text] [PDF]

				A. P. Heaney Pituitary tumour pathogenesis. Br. Med. Bull., January 1, 2006; 75-76: 81 - 97. [Abstract] [Full Text] [PDF]

				F. Canzian, J. D. McKay, R. J. Cleveland, L. Dossus, C. Biessy, C. Boillot, S. Rinaldi, M. Llewellyn, V. Chajes, F. Clavel-Chapelon, et al. Genetic Variation in the Growth Hormone Synthesis Pathway in Relation to Circulating Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Breast Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition Study Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2316 - 2325. [Abstract] [Full Text] [PDF]

				M. Filopanti, C. Ronchi, E. Ballare, S. Bondioni, A. G. Lania, M. Losa, S. Gelmini, A. Peri, C. Orlando, P. Beck-Peccoz, et al. Analysis of Somatostatin Receptors 2 and 5 Polymorphisms in Patients with Acromegaly J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4824 - 4828. [Abstract] [Full Text] [PDF]

				J. Bertherat, F. Tenenbaum, K. Perlemoine, C. Videau, J. L. Alberini, B. Richard, B. Dousset, X. Bertagna, and J. Epelbaum Somatostatin Receptors 2 and 5 Are the Major Somatostatin Receptors in Insulinomas: An in Vivo and in Vitro Study J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5353 - 5360. [Abstract] [Full Text] [PDF]

				A. Lania, G. Mantovani, and A. Spada Genetics of Pituitary Tumors: Focus on G-Protein Mutations Experimental Biology and Medicine, October 1, 2003; 228(9): 1004 - 1017. [Abstract] [Full Text] [PDF]

				A. Lania, M. Filopanti, S. Corbetta, M. Losa, E. Ballare, P. Beck-Peccoz, and A. Spada Effects of Hypothalamic Neuropeptides on Extracellular Signal-Regulated Kinase (ERK1 and ERK2) Cascade in Human Tumoral Pituitary Cells J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1692 - 1696. [Abstract] [Full Text] [PDF]

				L. J. Hofland and S. W. J. Lamberts The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance Endocr. Rev., February 1, 2003; 24(1): 28 - 47. [Abstract] [Full Text] [PDF]

				S. Corbetta, A. Lania, M. Filopanti, L. Vicentini, E. Ballare, and A. Spada Mitogen-Activated Protein Kinase Cascade in Human Normal and Tumoral Parathyroid Cells J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2201 - 2205. [Abstract] [Full Text] [PDF]

				A. Spada and P. Beck-Peccoz Editorial: New Strategy to Solve the Etiopathogenetic Conundrum of Pituitary Adenomas Endocrinology, February 1, 2002; 143(2): 343 - 346. [Full Text] [PDF]